Virology Journal, published by BMC, stands as a prominent open-access platform since 2004, dedicated to advancing the field of virology and infectious diseases. With its E-ISSN: 1743-422X, this journal is based in the United Kingdom and strives to disseminate high-quality research that enhances our understanding of viral pathogens and their interactions with hosts. Recognized with a Q1 classification in the category of Infectious Diseases and a Q2 in Virology for 2023, Virology Journal holds significant standing in the academic community, ranking #82/344 in Medicine - Infectious Diseases and #26/80 in Immunology and Microbiology - Virology. Its commitment to open access ensures that cutting-edge research is freely available to researchers, professionals, and students worldwide, fostering collaboration and innovation in the fight against viral diseases. The journal aims to publish original research articles, reviews, and commentaries that will stimulate discourse and spark new ideas within the virology community.

VIROLOGIE is a prominent international journal dedicated to advancing the field of virology and infectious diseases, published by John Libbey Eurotext Ltd. Since its inception in 1997, this journal has provided a platform for researchers and professionals to disseminate their findings on various aspects of virology, including the pathogenesis, epidemiology, and treatment of viral infections. Despite its current ranking in Q4 for both Infectious Diseases and Virology categories, the journal remains a valuable resource for emerging research and novel insights. The ISSN for the journal is 1267-8694, and it is based in France. VIROLOGIE is committed to upholding rigorous academic standards and fosters an inclusive scholarly community, making it an essential read for those pursuing knowledge and advancements in the ever-evolving landscape of virology. While the journal does not currently offer open access options, it continues to contribute significantly to the global discourse on viral research through its diverse range of published studies.

Virology, published by Academic Press Inc. Elsevier Science, is a prominent journal dedicated to advancing the knowledge and understanding of viral biology and pathogenesis since its inception in 1955. With a distinguished impact factor and recognized as a Q2 journal in the field of Virology for 2023, it ranks 38 out of 80 in the Scopus database for Immunology and Microbiology, placing it in the 53rd percentile among similar publications. This esteemed journal provides a platform for groundbreaking research, critical reviews, and comprehensive studies that contribute to our global understanding of viruses and their impact on health and disease. Although currently not an open-access journal, it remains accessible to a wide audience of researchers, professionals, and students who are keen to explore the latest advancements in virological research. The journal's scope encompasses a diverse range of topics, ensuring that it serves as an essential resource for anyone engaged in virology and related biomedical fields.

Future Virology, published by Future Medicine Ltd, is an essential journal dedicated to advancing the understanding of virology in the contemporary scientific landscape. With an ISSN of 1746-0794 and an E-ISSN of 1746-0808, this journal serves as a platform for researchers and practitioners in the field to publish high-quality, peer-reviewed articles that explore novel discoveries, innovative therapeutic strategies, and the implications of viral research on global health. Operating from the United Kingdom and maintaining a commitment to rigorous scientific inquiry, Future Virology is categorized in the Q4 Quartile for Virology according to the latest Scopus rankings, with a position of Rank #48/80 and a percentile of 40th in the Virology category. Although it currently does not offer open access, the journal strives to disseminate critical insights that benefit a wide range of professionals, researchers, and students engaged in virology and related fields. By bridging the gap between basic research and practical applications, Future Virology plays a crucial role in fostering innovation and collaboration in the ever-evolving virology landscape.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

Viruses-Basel, published by MDPI, is a leading interdisciplinary journal focused on the field of virology and infectious diseases, offering a platform for the rapid dissemination of high-quality research. Established in 2009, this open access journal has become an essential resource for researchers and health professionals, ensuring that critical findings are readily available to a global audience. With an impressive Q1 ranking in Infectious Diseases and a Q2 ranking in Virology as of 2023, the journal reflects its commitment to impactful research, validated by its notable positions within Scopus categories—ranked #84 out of 344 in Medicine: Infectious Diseases and #27 out of 80 in Immunology and Microbiology: Virology. The journal adheres to high standards of academic rigor, and by embracing an open access model, it promotes unrestricted access to scientific knowledge, fostering collaboration among researchers, professionals, and students alike. Situated in Basel, Switzerland, the journal serves as a cornerstone in the dissemination of research findings related to viral diseases and their implications on public health.